




Vaxsia
華西亞生醫


Introducing VADEX-Pro

A novel tool for developing therapeutic and diagnostic mAb




Benefit of VADEX-Pro over conventional adjuvant



1. No disruption of important epitopes due to hydrophobic interaction with oil adjuvant.
2. Protein nanoparticle embedded adjuvant remain active even in extremely low Ag concentration.
3. Polyvalent particle for activating B cell and clonal selection.
4. Push the immune sera binding affinity (KD) down to picomole level (10^{-11}) in 2 months.



External adjuvant (AddaVax)



VADEX-Pro



Limited availability promotions

To celebrate the unveiling of VADEX-pro Technology in ACVR 2024, VAXSIA is making a promotion for providing 10 VADEX-pro based protein nanoparticle preparation services at a discounted price.

The services provided in this promotion

1. 2 mg of lyophilized VADEX-pro protein nanoparticle incorporated with the antigen of your choice.
2. The expression of the protein of your choice in mammalian cell.
3. 100 μ g of your protein of choice lyophilized for assay.
4. A full license for developing monoclonal antibody derived products of any kind against the protein of your choice using purchased protein nanoparticle.

Only 10 slots available

Contact Dr. Kan for pricing and detail information: mingchung.kan@vaxsia.com